Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903069 · ClinicalTrials.gov registry record · Phase 1
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02903069 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 66 participants.
The verdict
NCT02903069, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of the tumor, and/or improving survival. Marizomib (MRZ) is being added to standard-of-care treatments of radiotherapy (RT), temozolomide (TMZ), and Optune.
Interventions
- DRUG TMZ
- DEVICE Optune
- DRUG MRZ
- RADIATION RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903069
The ClinicalTrials.gov registry entry for NCT02903069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which TMZ is the first listed.
NCT02903069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903069 about?
NCT02903069 is a clinical study titled "Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer". This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of the tumor, and/or improving su...
What is the current status of trial NCT02903069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2016-08-17. Estimated completion is 2021-01-25.
What interventions are being tested in trial NCT02903069?
The interventions under investigation include: TMZ (DRUG), Optune (DEVICE), MRZ (DRUG), RT (RADIATION).
Who is sponsoring clinical trial NCT02903069?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.